Pharmacokinetic profiling via dried blood spot sampling method

PELCOVÁ, Marta, Eva KREJČÍŘOVÁ, Miriam ŠTOLCOVÁ, Jan JUŘICA and Zdeněk GLATZ. Pharmacokinetic profiling via dried blood spot sampling method. In Synthesis and Analysis of Drugs. 2022.

Basic information

• Original name: Pharmacokinetic profiling via dried blood spot sampling method
• Name in Czech: Farmakokinetické profilování pomocí metody suché krevní kapky
• Name (in English): Pharmacokinetic profiling via dried blood spot sampling method
• Authors: PELCOVÁ, Marta, Eva KREJČÍŘOVÁ, Miriam ŠTOLCOVÁ, Jan JUŘICA and Zdeněk GLATZ.
• Edition: Synthesis and Analysis of Drugs, 2022.

Other information

• Type of outcome: Presentations at conferences
• Confidentiality degree: is not subject to a state or trade secret
• Keywords (in Czech): aplikovaná farmakokinetika, suchá krevní skrvna, serie vzorků
• Keywords in English: applied pharmacokinetics, dried blood spot, serial sampling

Abstract

Pharmacokinetic (PK) profiles are still an inevitable part of preclinical safety studies. Generally, PK studies require the collection of a series of blood samples in sufficient volumes (usually about 200 µl). Typically, animal protocols limit the total blood draw between 10 and 15 % of the total blood volume allowed within a 2-week period. Further, animal models are subjected to ethical standards to be carefully monitored and principles of the 3Rs are required: replacement, reduction and refinement. Our pilot PK study of clozapine (CLO) was conducted in a single Wistar albino rat. CLO was administrated subcutaneously in a single dose bolus (20 mg/kg) and blood samples were taken from a retroorbital plexus by a calibrated glass capillary and spotted onto the card (Whatman 903 Protein Saver Card). CLO concentrations were acquired by LC-MS method and corresponding PK parameters were calculated by Kinetica 4.4 software. The obtained parameters are in agreement with data from a large cohort study.

Abstract (in Czech)

Farmakokinetické profilování je stále nedílnou součástí preklinických studií. Pro provedení farmakokinetické studie je potřeba odebrat sérii vzorků krve v dostatečném objemu (okolo 200 µl). Standardně je povoleno odebrat testovanému zvířeti maximálně 15 % celkového objemu krve s dvoutýdenní rekonvalescencí. Pro takové studie modelová zvířata podléhají etickým standardům, které jsou důsledně sledovány a princily 3R vyžadovány: tj. náhrada, snížení a zmírnění. naše pilotní PK studie za využití klozapinu (CLO) byla provedena je jednom jediném zvířeti (wistarská krysa). CLO byl podán jednorázově a vzorky krve byly odebírány z retroorbitálního plexu kalibrovanou kapilárou a naneseny na odběrovou kartu (Whatman 903 Protein Saver Card). Koncentrace CLO byly měřeny LC-MS metodou a odpovídající farmakokinetické parametry byly vypočteny pomocí softwaru Kinetica 4.4. Získané parametry byly ve shodě s publikovanými údaji.

Abstract (in English)

Pharmacokinetic (PK) profiles are still an inevitable part of preclinical safety studies. Generally, PK studies require the collection of a series of blood samples in sufficient volumes (usually about 200 µl). Typically, animal protocols limit the total blood draw between 10 and 15 % of the total blood volume allowed within a 2-week period. Further, animal models are subjected to ethical standards to be carefully monitored and principles of the 3Rs are required: replacement, reduction and refinement. Our pilot PK study of clozapine (CLO) was conducted in a single Wistar albino rat. CLO was administrated subcutaneously in a single dose bolus (20 mg/kg) and blood samples were taken from a retroorbital plexus by a calibrated glass capillary and spotted onto the card (Whatman 903 Protein Saver Card). CLO concentrations were acquired by LC-MS method and corresponding PK parameters were calculated by Kinetica 4.4 software. The obtained parameters are in agreement with data from a large cohort study.

Links

• MUNI/G/1464/2018, interní kód MU: Name: Nové směry v bioanalytických přístupech pro personalizovanou farmakoterapii schizofrenie (Acronym: TDM olanzapinu v DBS)

Investor: Masaryk University, INTERDISCIPLINARY - Interdisciplinary research projects